Nose organoids reveals first stages of SARS-CoV-2 and respiratory syncytial virus infection
Using nose organoids, researchers have highlighted key differences between the infection by SARS-CoV-2 and that of respiratory syncytial virus.
List view / Grid view
Using nose organoids, researchers have highlighted key differences between the infection by SARS-CoV-2 and that of respiratory syncytial virus.
The University at Buffalo has received a $2.3 million grant from the US National Cancer Institute to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.
In a new study, researchers have demonstrated the efficiency of T-cell immune response against the Omicron variant of SARS-CoV-2.
Researchers have been able to reduce the chronic inflammation associated with multiple sclerosis in a mice model of the disease, by administering one of the resolving lipid mediators of inflammation, Maresin-1.
The new findings could help scientists to identify new targets and develop initial concepts to better restrain the metastatic spread of breast cancer.
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
Scientists have created a tiny, bioengineered 3D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, a pair of rare, devastating neuromuscular diseases.
Scientists have successfully created viable organoids from tumour samples from five patients with a rare bone cancer called a chordoma, which has few therapeutic options.
Scientists at the Endocrine Society have found extracellular vesicles may offer new insights into treating endocrine disorders.
Interview with Michael Schwenkert, Bio-Rad Laboratories, on best practices for the characterisation and quality control of anti-idiotypic antibodies for bioanalysis.
A new screening assay could be used to identify new drugs to treat resistant forms of prostate cancer.
Researchers have found how ovarian cancer tumours defy immunotherapy, identifying new molecular targets that might boost immune response.
Scientists report news of a promising new compound that effectively blocks the activity of proteins on cells that are necessary for SARS-CoV-2 to cause infection.
Drug Target Review's Editor Victoria Rees brings you the highlights from the American Association for Cancer Research Meeting 2022.
14 April 2022 | By Eurofins Discovery Services
Watch this free on-demand webinar to understand how to rapidly identify selective, specific, potent and tractable hit series with appropriate ADME characteristics to speed up hit-to-lead.